Efficacy of Intralesional Betamethasone Versus Triamcinolone Acetonide in the Treatment of Alopecia Areata

The study compared the efficacy and safety of intralesional betamethasone and triamcinolone acetonide in treating alopecia areata. Conducted as a double-blind, randomized controlled trial with 12 patients, each alopecia plaque was divided into four quadrants, receiving different treatments: triamcinolone acetonide 2.5 mg/ml, betamethasone 0.375 mg/ml, betamethasone 1.75 mg/ml, or placebo. Triamcinolone acetonide showed the best results at 4 and 8 weeks, but by the end of the study, both triamcinolone acetonide and betamethasone 1.75 mg/ml had similar efficacy, significantly outperforming betamethasone 0.375 mg/ml and placebo. No adverse effects were observed, suggesting that betamethasone 1.75 mg/ml is a safe and effective option for treating localized alopecia areata.